Toyota Yaris Launch in India: Honda City likely to lose more
Toyota Yaris’s launch with an aggressive pricing will surely disturb the status quo in Mid-size Sedan segment in India.
In this study, we will be analyzing who will be getting impacted most by Toyota’s new arrival. We will be taking top 3 players from mid-size sedan segment as these names occupy close to 85% market share in a relatively less crowded segment. The top 3 models include Honda City, Maruti Suzuki Ciaz, and Hyundai Verna.
Honda City is by far the largest selling model of Honda in India, constituting 31% of company’s total sales (1Q-18). Hyundai Verna, launched in 3Q-17, has been the largest gainer in the segment. Its market share has picked to 29% in 1Q-18 from 6% in 1Q-17. Unlike Honda’s City, Hyundai’s reliance on the model is much less and Verna constituted just 9% of Hyundai’s total sales in India in 1Q-18.
Maruti Suzuki’s Ciaz was launched in 4Q-14. Given MSIL’s diverse small car portfolio, its reliance on Ciaz is minimal. We believe that any disruption by a new arrival will have little impact on it. A Ciaz facelift is also expected in August this year and this should help the model in capturing some lost ground. Ciaz’s market stood at 32% in Mid-size sedan segment in 1Q-18, down 560 bps vs. 1Q-17.
[Compare screen: PV Unit sales for top 3 models]
Given Honda’s reliance on City and time gap from now for its next-generation launch (2020), we suspect City to be the most vulnerable of the lot from Yaris aggressive launch. We understand that City has a loyal customer base. However, recent onslaught of the launches dented its market share.
Heckyl’s alternative data platform, FiND collects and organizes macro, micro, and financial data to provide unique insights into automobile sector.
To know more about FiND, email us at email@example.com
India Commercial Vehicle sector on a strong growth path
Low base likely to push growth further in coming months
The Commercial Vehicle (CV) sector, which is considered to be the barometer of an economy, recorded a surge of 19.9% in unit sales during FY18. The remarkable feature of this growth has been recovery post GST implementation (Image 1). Overall sales of CVs increased by 34% and 31% respectively in Q4CY17 and Q1CY18 after a decline of 9% in Q2CY17.
[Image 1: India CV quarterly unit sales and y-o-y change]
At the same time, the 12-month moving sum of CV sales witnessed sharp northwards movement post July-17 (Image 2). We assign this surge to fleet owners’ bulk buying post GST implementation. Moreover, this trend is expected to continue in coming months given improved macro-conditions at ground level, huge pent-up demand, the higher average age of the fleet and lower comparable (Q2CY17 was down 9% y-o-y).
[Image 2: India CV unit sales 12-month moving sum] Read the rest of this entry »
Japan Airlines delivers industry-beating on-time performance; Air India consistently lags on punctuality
The on-time performance (OTP) is one of the most important performance indicators for airlines. It shows how frequently the airline has managed to operate flights within the declared scheduled time.
OTP is a measure of service quality/ punctuality. The higher OTP can help airlines to meet its customer expectations. At the same time, improvement in customer service can also boost airline’s profitability.
Over the past 24-months, OTP for Japan Airlines has consistently outperformed the industry average. On the other hand, OTP for state-run Air India has consistently remained below the industry average in the last 24-months except April 2017.
Heckyl’s alternative data platform FiND collects and organizes macro, micro, and financial data to provide unique insights into aviation sector.
To know more about FiND, email us at firstname.lastname@example.org
Track clinical trials in FiND Calendar to spot new opportunities in pharma sector
With a clear focus on reduction of the information arbitrage, Heckyl has built an alternative data platform FiND which collects and organizes macro, micro, and financial data to provide unique insights into pharmaceutical sector.
In our view, trading opportunities can be spotted in the stock market by discovery and analysis of vast amount of alternative data available on the web. One such data set is clinical trial study results for pharmaceutical companies.
Clinical trials are research studies that explore whether a drug or device is safe and effective for humans. The pharmaceutical products go through three phases of clinical trials followed by a regulatory approval process. After completing all three phases and the approval process, the company can start monetizing the drug or device.
The drugmakers report the progress of ongoing clinical trials for each phase from time to time. The result of late study trials (phase 2 and 3) can provide the best idea about a drug’s chances of approval. A favorable result of late study trials can be seen as positive by the market and vice-versa.
To help traders/ investors, we have introduced Calendar which tracks release dates for clinical trial, drug approval, patent expiry, operating stats and industry events.
We present a case study on Clearside Biomedical, Inc., a late-stage biopharmaceutical company developing drug therapies to treat back-of-the-eye diseases.
On Mar. 5, 2018, Clearside announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis (Image 1).
(Image 1: News screen for Clearside) Read the rest of this entry »
Insight from FiND: Did you MISS the recent opportunity to short Facebook?
FiND, an alternative data platform, analyses news + data from thousands of sources (including social media) in real time. We have a clear focus on reduction of the information arbitrage by “discovery and analysis” of the news flow in real time. Our proprietary Sentiment Engine analyzes news by applying NLP and various business rules to capture underlying sentiment (positive/ negative/ neutral) accurately.
Earlier this week, the shares of Facebook were beaten down at the Wall Street due to a privacy failure by the social media giant. It’s surfaced that Cambridge Analytica improperly used the data of 50 million Facebook users to manipulate voters in US Presidential Election 2016.
News reports highlighting concerns over privacy of FB users’ data and misuse of social network platform have been making the rounds across mainstream media for months now. The negative media coverage highlighting these concerns gathered momentum during this month. However, the stock corrected sharply only after the media reported the misuse of FB users data by Cambridge Analytica. We highlight some of the news items captured by FiND below:
[Image 1: Company News Screen for FB] Read the rest of this entry »
- ← Previous
- Next →